EIGR Reddit Mentions | ChartExchange

**Background and Ron Perelman of SS Fame**
VTVT has existed in obscurity for years. We are talking a mere few thousand in daily volume. It makes sense given it's history. Until recently it was almost entirely owned by Ron Perelman - who took REV private and once had a net worth of around 20b. (If you recall, Ron was aggro with his position size with REV and that resulted in REV seeing many beautiful squeezes) Hence the company has little reason to be promotional. On top of that, their cash position was severely limited and they cut their operations and research to the bone. My assumption was Perelman was reluctant to dilute his position and content to see how the lead candidate developed over a longer timeframe.
**Pipeline**
Anyway, this company is focused on treatments for diabetes and towards that end developed and took oral glp-1 to phase II. Around 2017 they licensed that to a company in china. That deal ended in late 2023, and they now seem to be shopping around for alternatives. **The important thing to note here is they have been in the glp-1 / metabolism space for many years, and this is not some dogshit asset they threw on the books when glp-1 starting trending. On the contrary, they have been very low key.**
[https://vtvtherapeutics.com/pipeline/](https://vtvtherapeutics.com/pipeline/)
https://preview.redd.it/bkf8v1v5nlcd1.png?width=1045&format=png&auto=webp&s=d3bf1f1ac535a6b52e12cd34dc77b00ed79ec629
**Ownership**
Meanwhile they raised around $50m in cash, reducing Perelman's stake to \~60% ownership but adding some notable tutes to the list of stakeholders. As it stands now, it is almost entirely owned by Perelman + a handful of tutes. The funding was for TTP399, a GK activator.
Now add that shit up. How much is left for the plebes?
[https://whalewisdom.com/stock/vtvt](https://whalewisdom.com/stock/vtvt)
https://preview.redd.it/w2bg9fd9mlcd1.png?width=629&format=png&auto=webp&s=105f9978eb6349a69cd706a5e72900eb413d262f

**The Fundamentals**
In sum, the company is trading at \~7m enterprise value, has \~50m in cash, has a promising least asset in TTP399, is being tightly held by a shrewd set of investors, and thanks to a timely deal termination has a phase II oral glp-1 they are actively looking to do something with.

**EIGR Case Study**
EIGRQ provides an interesting reference. They also had a phase II glp-1 that the market seemingly overlooked, and when they landed a deal for it last month, the stock price increased from the 3s to the 13s.
https://preview.redd.it/73bvzk3xllcd1.png?width=788&format=png&auto=webp&s=964069c9321ab2b6a517d356810cf1d51f8aa877
I think VTVT could likewise potentially squeeze on a deal announcement with their oral glp-1, and even without that is possibly greatly undervalued based on the potential of TTP399.
**Further References**
PRs for the original deal and recent termination
[https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-licensing-agreement-hangzhou-zhongmei](https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-licensing-agreement-hangzhou-zhongmei)
[https://www.streetinsider.com/Corporate+News/vTv+Therapeutics+(VTVT)+Receives+Notice+of+Termination+of+License+Agreement+from+Hangzhou+Zhongmei+Huadong/22561706.html](https://www.streetinsider.com/Corporate+News/vTv+Therapeutics+(VTVT)+Receives+Notice+of+Termination+of+License+Agreement+from+Hangzhou+Zhongmei+Huadong/22561706.html)

Details on the oral glp-1
[https://vtvtherapeutics.com/pipeline/ttp273/](https://vtvtherapeutics.com/pipeline/ttp273/)